

63. MDR-TB: detection, prevalence, and drivers
Sunday, 06 December 2015, 12:15-13:15

Chair: Helen COX (South Africa)

Track: TB laboratory services: organisation and quality assurance

PC-1229-06 Why MDR-TB patients do not accept treatment

Z Xu, L Bai (*China*)

PC-1230-06 RNTCP experience in rolling out base-line second-line drug susceptibility testing among MDR-TB cases

M Ghedia, Ks Sachdeva, A Amar Shah, S Anand, P Parmar, R Ramachandran, A Sreenivas, F Sayyed Imran (*India*)

PC-1231-06 Genetic characterization of multidrug-resistant Mycobacterium tuberculosis strains from various regions of Delhi

J Arora, Z Sidiq, Manp Bhalla, P Visalakshi, Vith Myneedu, U Singh, D Behera, R Sarin (*India*)

PC-1232-06 Multidrug-resistant tuberculosis among foreign-born persons in Japan

N Kobayashi, T Hattori, T Kirikae, S Kato, J Suzuki, K Ohta (*Japan*)

PC-1233-06 Drug-resistant tuberculosis and risk factors of multidrug resistance in Ukraine: results of the first nationwide survey

E Pavlenko, A Barbova, A Hovhannesian, Z Tsenilova, A Slavuckij, A Dean, M Dara, A Dadu (*Ukraine, Armenia, Switzerland, Denmark, Moldova*)

PC-1234-06 Prevalence of MDR-TB and drug resistance patterns in retreatment cases in Punjab, Pakistan

A Majeed, M Awais Arif, H Javed, S Kanwal (*Pakistan*)

PC-1235-06 Estimating true MDR prevalence rates using routinely collected data

Z McLaren, R Burger (*USA*)

PC-1236-06 Drug resistance patterns in MDR-TB patients: challenges for future regimen design

H Stagg, J Brown, E Ibraim, V Riekstina, P Viiklepp, G Dravniece, C Jackson, P White (*UK, Estonia, Switzerland*)